AMRX

Amneal Pharmaceuticals Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth 8/10
  • Value 6/10
Amneal Pharmaceuticals sales and earnings growth
AMRX Growth
Good
  • Revenue Y/Y 8.05%
  • EPS Y/Y 160.53%
  • FCF Y/Y 3.61%
Amneal Pharmaceuticals gross and profit margin trends
AMRX Profitability
Neutral
  • Gross margin 36.90%
  • EPS margin 2.40%
  • ROIC 5Y 4.73%
Amneal Pharmaceuticals net debt vs free cash flow
AMRX Risk
Poor
  • Debt / Equity 999.0
  • Debt / FCF 9.8
  • Interest coverage 1.4

Amneal Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗